Published in Ther Adv Psychopharmacol on December 01, 2014
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet (2000) 6.78
What clinicians should know about the QT interval. JAMA (2003) 4.45
Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry (2007) 2.41
Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol (2009) 1.57
Influence of heart rate and inhibition of autonomic tone on the QT interval. Circulation (1982) 1.30
Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol (2003) 1.15
Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development? J Pharmacol Toxicol Methods (2008) 1.14
Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis (2001) 1.09
Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother (1997) 0.99
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry (2001) 0.97
Beat-to-beat QT interval variability is primarily affected by the autonomic nervous system. Ann Noninvasive Electrocardiol (2008) 0.91
Effect of autonomic nervous function on QT interval in dogs. J Toxicol Sci (2005) 0.87
Influence of autonomic tone on QT interval duration. Cardiologia (1997) 0.85
[Long QT syndrome due to olanzapine administration]. Kardiol Pol (2006) 0.81
Prolongation of QTc interval and antipsychotics. Am J Psychiatry (2002) 0.80